Active Ingredient(s): Tafamidis Meglumine
FDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyndaqel Overview

Tafamidis (trade name Vyndaqel)[1] is a drug used to delay loss of peripheral nerve function in adults with familial amyloid polyneuropathy (FAP), an orphan disease. It works by stabilizing the protein, transthyretin, which is normally made up of four strands. In people with FAP these strands separate and form clumps that harm nerves. In May 2019, the FDA approved two preparations tafamidis meglumine and tafamidis, for the treatment of transthyretin mediated cardiomyopathy ...

Read more Vyndaqel Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tafamidis

Recent Vyndaqel Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tafamidis Meglumine
  • Capsule: 20mg, 61mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vyndaqel: (2 results)

Sorted by National Drug Code
  • 0069-1975 Vyndaqel 20 mg Oral Capsule, Liquid Filled by Pfizer Laboratories Div Pfizer Inc
  • 0069-8729 Vyndaqel by Pfizer Labs Division of Pfizer Inc.

Other drugs which contain Tafamidis Meglumine or a similar ingredient: (2 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 August 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA